Scientists behind Purespring Therapeutics Ltd. have made progress in overcoming the problems of accessibility, complexity of structure and diversity of cell types that have held back the use of gene therapy in the kidneys, reporting success in treating nephrotic syndrome in a mouse model of the inherited form of the renal disease. Read More
A different class of antibiotics could ease the increasing resistance triggered by some gram-negative bacteria. LpxC inhibitors are not new, but all attempts to develop them have failed due to cardiovascular toxicity or ineffectiveness. A modification of the structure of these compounds may have solved the problem. Duke University scientists demonstrated the preclinical safety and efficacy of an LpxC inhibitor candidate against a wide selection of these pathogens. Read More
Georgiamune Inc. announced that the FDA cleared its IND application for GIM-122, a first-in-class dual-functioning monoclonal antibody designed to target a highly novel mechanism to overcome immunotherapy resistance. Read More
Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine (CIRM) to support three novel phase I clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia (AML) and severe aplastic anemia. Read More
Researchers from Acerand Therapeutics (Hong Kong) Ltd. have presented Poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer, metabolic diseases, cardiovascular, inflammatory, psychiatric and immunological disorders. Read More
Diabetes has been associated with increased bone fracture risks, however, the cellular and molecular mechanisms underlying diabetic bone fragility are not clear. In the current study, researchers from the Children's Hospital of Philadelphia presented data from a study that aimed to investigate these mechanisms in murine monogenic model of type 1 diabetes (T1D). Read More
Shanghai Lisen Imprinting Pharmaceutical Technology Co. Ltd. has disclosed EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of small-cell lung (SCLC) and l lung cancer (NSCLC). Read More
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer. Read More
Lemonex Inc. announced that the IND application for its mRNA vaccine candidate LEM-mR203 has been approved by the Korean Ministry of Food and Drug Safety (MFDS) on July 21, 2023. The company plans to evaluate LEM-mR203 as potential treatment for COVID-19, with the planned phase I clinical trial being designed to assess its safety and immunogenicity in healthy adults at Seoul National University Hospital, Korea. Read More
Guangzhou Lupeng Pharmaceutical Co. Ltd. and Newave Pharmaceutical LLC have divulged (mutant) ligands reported to be useful for the treatment of cancer, autoimmune disease and inflammation. Read More
Oncovalent Therapeutics Inc. has patented SUMO-activating enzyme subunit 1 (SAE1) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from the University of Texas System presented preclinical data for MC-1-F2, a direct small molecule inhibitor of forkhead box protein C2 (FOXC2). The candidate has previously shown activity in breast cancer cell lines, and the current study aimed to assess its efficacy in castration-resistant prostate cancer (CRPC). Read More
